Craft Health and PharmaTher Test 3D Printing for Personalized Peptides

A New Era in Pharmaceutical Manufacturing: 3D Printing for Personalized Peptides \\[PharmaTher Holdings](https://www.pharmather.com/) and [Craft Health Pte. Ltd.](https://www.crafthealth.sg/), a Singapore-based pharmaceutical technology company, have announced a collaboration to explore the potential of 3D printing for producing personalized peptide doses. This partnership, announced on July 29, 2026, comes just two days after PharmaTher launched its Personaliz3D Peptides division, aiming to bring a new level of customization to the pharmaceutical industry. The focus of this collaboration will be on six peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, which were recently recommended by the FDA's Pharmacy Compounding Advisory Committee (PCAC) for inclusion on the Section 503A Bulks List. If adopted, this recommendation would open a regulated path for pharmacies to compound these peptides, and PharmaTher is positioning 3D printing as the preferred manufacturing method. \\[The current model of peptide therapy](https://www.3dprintingindustry.com/news/craft-healths-craftmake-platform-gets-a-peptide-test-run-184726/) often involves fixed-dose injectables, with limited room for customization. This can lead to suboptimal treatment outcomes, as individual patient needs may vary significantly. By leveraging 3D printing, PharmaTher aims to address these gaps through a three-part plan: Connect, Personalize, and Deliver. This includes a telemedicine platform to link patients with prescribers, 3D printing and AI tools to create patient-specific formulations, and partnerships with 503A pharmacies to prepare and dispense these customized treatments. \\[Craft Health's CraftMake 3D printing platform](https://www.3dprintingindustry.com/news/craft-healths-craftmake-platform-gets-a-peptide-test-run-184726/) is designed to handle sensitive active ingredients without heat or UV exposure, which can degrade peptides. The platform includes a GMP-oriented version, CraftMake Production Plus, which operates in an enclosed environment with dual printheads, ensuring high dosing accuracy and repeatability. Additionally, CraftControl, a workflow software, and CraftBlends, a formulation database, support the entire process, from design to production. \\[For factories in Thailand, Vietnam, Indonesia, and Malaysia, this development could mean significant advancements in pharmaceutical manufacturing.](https://www.aseanmachine.com/) The ability to produce personalized medications on-site, with high precision and consistency, could reduce reliance on centralized manufacturing and distribution, leading to more efficient and cost-effective operations. Moreover, the integration of 3D printing and AI technologies can enhance the quality and safety of pharmaceutical products, benefiting both manufacturers and end-users. \\[In conclusion, the collaboration between PharmaTher and Craft Health represents a promising step towards a more personalized and efficient pharmaceutical industry.](https://www.aseanmachine.com/) For factory buyers in ASEAN, this means the potential to adopt cutting-edge 3D printing technology, enabling them to stay at the forefront of pharmaceutical innovation and meet the growing demand for customized treatments.